Production of recombinant protein using the HeLa S3-vaccinia virus expression system: Bioreactor perfusion and effects of post-infection temperature

Bioscience, Biotechnology and Biochemistry

Volumn 69, Issue 6, 2005, Pages 1065-1072

  Bleckwenn, Nicole A ^a,b   Bentley, William E ^b   Shiloach, Joseph ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Enhanced green fluorescent protein (EGFP); HeLa S3; Hollow fiber; Perfusion; Vaccinia

Indexed keywords

BIOREACTORS; CELLS; FIBERS; FLUORESCENCE; VIRUSES;

CELL DENSITY; MULTIPLICITY OF INFECTION (MOI); RECOMBINANT PROTEIN; SUSPENSION CULTURE;

PROTEINS;

ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; RECOMBINANT PROTEIN;

ARTICLE; BIOREACTOR; BIOSYNTHESIS; GENE EXPRESSION; GENE VECTOR; GENETICS; HELA CELL; HUMAN; METABOLISM; TEMPERATURE; TIME; VACCINIA VIRUS;

BIOREACTORS; GENE EXPRESSION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; RECOMBINANT PROTEINS; TEMPERATURE; TIME FACTORS; VACCINIA VIRUS;

VACCINIA; VACCINIA VIRUS;

EID: 22444444321     PISSN: 09168451     EISSN: None     Source Type: Journal    
DOI: 10.1271/bbb.69.1065     Document Type: Article

References (30)

1. Hooper, K. P., Padmanabhan, R., and Ebner, K. E., Expression of the extracellular domain of the rat-liver prolactin receptor and its interaction with ovine prolactin. J. Biol. Chem., 268, 22347-22352 (1993).
2. Jun, S. C., Lee, G. M., Chang, S. H., and Kim, J. H., Effect of serum type and concentration on the expression of β-galactosidase in recombinant vaccinia virus infected HeLa S3 cells. Cytotechnology, 19, 153-159 (1996).
3. Gomella, L. G., Mastrangelo, M. J., McCue, P. A., Maguire, H. C., Mulholland, S. G., and Lattime, E. C., Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol., 166, 1291-1295 (2001).
4. Hanlon, C. A., Niezgoda, M., Hamir, A. N., Schumacher, C., Koprowski, H., and Rupprecht, C. E., First North American field release of a vaccinia-rabies glycoprotein recombinant virus. J. Wildl. Dis., 34, 228-239 (1998).
5. Zajac, P., Oertli, D., Marti, W., Adamina, M., Bolli, M., Guller, U., Noppen, C., Padovan, E., Schultz-Thater, E., Heberer, M., and Spagnoli, G., Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther., 14, 1497-1510 (2003).
6. Hanke, T., McMichael, A. J., Mwau, M., Wee, E. G. T., Ceberej, I., Patel, S., Sutton, J., Tomlinson, M., and Samuel, R. V., Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine, 20, 1995-1998 (2002).
7. McClain, D. J., Summers, P. L., Harrison, S. A., Schmaljohn, A. L., and Schmaljohn, C. S., Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol., 60, 77-85 (2000).
8. McAneny, D., Ryan, C. A., Beazley, R. M., and Kaufman, H. L., Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann. Surg. Oncol., 3, 495-500 (1996).
9. Cooney, E. L., McElrath, M. J., Corey, L., Hu, S. L., Collier, A. C., Arditti, D., Hoffman, M., Coombs, R. W., Smith, G. E., and Greenberg, P. D., Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. U.S.A., 90, 1882-1886 (1993).
10. Graham, B. S., Belshe, R. B., Clements, M. L., Dolin, R., Corey, L., Wright, P. F., Gorse, G. J., Midthun, K., Keefer, M. C., Roberts, N. J., Schwartz, D. H., Agosti, J. M., Fernie, B. F., Stablein, D. M., Montefiori, D. C., Lambert, J. S., Hu, S. L., Esterlitz, J. R., Lawrence, D. N., and Koff, W. C., Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J. Infect. Dis., 166, 244-252 (1992).
11. Cooney, E. L., Collier, A. C., Greenberg, P. D., Coombs, R. W., Zarling, J., Arditti, D. E., Hoffman, M. C., Hu, S. L., and Corey, L., Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet, 337, 567-572 (1991).
12. Wiktor, T. J., Macfarlan, R. I., Reagan, K. J., Dietzschold, B., Curtis, P. J., Wunner, W. H., Kieny, M. P., Lathe, R., Lecocq, J. P., Mackett, M., Moss, B., and Koprowski, H., Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. U.S.A., 81, 7194-7198 (1984).
13. Moss, B., Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U.S.A., 93, 11341-11348 (1996).
14. Moss, B., Vaccinia virus: A tool for research and vaccine development. Science, 252, 1662-1667 (1991).
15. Ward, G. A., Stover, C. K., Moss, B., and Fuerst, T. R., Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells. Proc. Natl. Acad. Sci. U.S.A., 92, 6773-6777 (1995).
16. Bleckwenn, N. A., Bentley, W. E., and Shiloach, J., Exploring vaccinia virus as a tool for large-scale recombinant protein expression. Biotechnol. Progr., 19, 130-136 (2003).
17. Bleckwenn, N. A., Bentley, W. E., and Shiloach, J., Evaluation of production parameters with the vaccinia virus expression system using microcarrier attached HeLa cells. Biotechnol. Progr., 21, 554-561 (2005).
18. Hu, Y. C., Kaufman, J., Cho, M. W., Golding, H., and Shiloach, J., Production of HIV-1 gp120 in packed-bed bioreactor using the vaccinia virus/T7 expression system. Biotechnol. Progr., 16, 744-750 (2000).
19. Barrett, N., Mitterer, A., Mundt, W., Eibl, J., Eibl, M., Gallo, R. C., Moss, B., and Dorner, F., Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS Res. Hum. Retrovir., 5, 159-171 (1989).
20. Zhang, S., Handacorrigan, A., and Spier, R. E., A comparison of oxygenation methods for high-density perfusion cultures of animal cells. Biotechnol. Bioeng., 41, 685-692 (1993).
21. Kyung, Y. S., Peshwa, M. V., Gryte, D. M., and Hu, W. S., High density culture of mammalian cells with dynamic perfusion based on on-line oxygen uptake rate measurements. Cytotechnology, 14, 183-190 (1994).
22. Chen, Y. K., Laporte, T. L., Wang, S. S., and Shevitz, J., High density culture of HeLa cells in a CelliGen perfusion system. Cytotechnology, 8, 85-88 (1992).
23. Dee, K. U., and Shuler, M. L., Mathematical model of the trafficking of acid-dependent enveloped viruses: application to the binding, uptake, and nuclear accumulation of baculovirus. Biotechnol. Bioeng., 54, 468-490 (1997).
24. Schlaeger, E. J., and Lundstrom, K., Effect of temperature on recombinant protein expression in Semliki Forest Virus infected mammalian cell lines growing in serum-free suspension cultures. Cytotechnology, 28, 205-211 (1998).
25. Bleckwenn, N. A., and Shiloach, J., Large-scale cell culture. In "Current Protocols in Immunology", eds. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W., John Wiley and Sons, New York, pp. A1.U.1-A1.U.44 (2004).
26. Gotoh, T., Miyazaki, Y., Chiba, K., and Kikuchi, K., Significant increase in recombinant protein production of a virus-infected Sf-9 insect cell culture of low MOI under low dissolved oxygen conditions. J. Biosci. Bioeng., 94, 426-433 (2002).
27. Hu, Y. C., and Bentley, W. E., Effect of MOI ratio on the composition and yield of chimeric infectious bursal disease virus-like particles by baculovirus co-infection: deterministic predictions and experimental results. Biotechnol. Bioeng., 75, 104-119 (2001).
28. Blasey, H. D., Lundstrom, K., Tate, S., and Bernard, A. R., Recombinant protein production using the Semliki Forest Virus expression system. Cytotechnology, 24, 65-72 (1997).
29. Dalal, N. G., and Bentley, W. E., Mathematical characterization of insect cell (Sf-9) death in suspended culture. Biotechnol. Lett., 21, 325-329 (1999).
30. Chillakuru, R. A., Ryu, D. D. Y., and Yilma, T., Propagation of recombinant vaccinia virus in HeLa cells: adsorption kinetics and replication in batch cultures. Biotechnol. Prog., 7, 85-92 (1991).